Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Hematology | Musculoskeletal
 Disease Category: Myelofibrosis
Location: United States, ND

Trial Information

Myelofibrosis

Study of the JAK Inhibitor INCB018424 tablet administered orally to subjects with primary myelofibrosis, post-polycythemia vera-myelofibrosis or post-essential thrombocythemia-myelofibrosis

Patient Inclusion Criteria:

  • 18 + years of age,
  • diagnosis of PMF or PPV-MF, either resistant or refractory to, intolerant of, or in the investigator's opinion not candidates for available therapy, must have a life expectancy of at least 6 months

Patient Exclusion Criteria:

  • Subjects with a life expectancy of less than 6 months, subjects in whom MF disease is well controlled with current therapy, females who are pregnant or currently breastfeeding, subjects with inadequate bone marrow, subjects with inadequate liver or renal function, subjects with cardiac disease, subject with currently uncontrolled or unstable angina

Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Phone: 701-751-1128
Fax: 701-751-1131
Email: tdavis.legacy@midconetwork.com

View Map

Research Center Information: Legacy Pharma Research

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.